Viferon suppositories 3000000ME, No. 10

• Acute respiratory viral infections, including influenza, including those complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy;

• infectious and inflammatory diseases of newborns, including premature babies: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy;

• chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of pronounced activity, complicated by liver cirrhosis;

• infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults as part of complex therapy;

• primary or recurrent herpes infection of the skin and mucous membranes, localized form, mild and moderate course, including the urogenital form in adults;

• viral meningitis in children aged 4 years and older as part of complex therapy.

The drug is used rectally. 1 suppository contains recombinant human interferon alpha-2b as an active substance in the indicated dosages (150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU).

Acute respiratory viral infections, including influenza, including those complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy. The recommended dose for adults, including pregnant women and children over 7 years old, VIFERONЃ 500,000 IU, 1 suppository 2 times a day every 12 hours every day for 5 days. According to clinical indications, therapy can be continued. Children under 7 years of age, including newborns and premature infants with gestational age over 34 weeks, are recommended to use VIFERONЃ 150,000 IU 1 suppository 2 times a day every 12 hours every day for 5 days. According to clinical indications, therapy can be continued. The break between courses is 5 days.Premature newborns with gestational age less than 34 weeks are recommended to use VIFERONЃ 150,000 IU 1 suppository 3 times a day every 8 hours every day for 5 days. According to clinical indications, therapy can be continued. The break between courses is 5 days.

Infectious and inflammatory diseases of newborns, including premature babies: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy. The recommended dose for newborns, including premature babies with a gestational age of more than 34 weeks, VIFERONЃ 150,000 IU daily, 1 suppository 2 times a day after 12 hours. The course of treatment is 5 days. Premature infants with gestational age less than 34 weeks are recommended to use VIFERONЃ 150,000 IU daily, 1 suppository 3 times a day after 8 hours. The course of treatment is 5 days. The recommended number of courses for various infectious and inflammatory diseases: sepsis - 2-3 courses, meningitis - 1-2 courses,herpes infection - 2 courses, enterovirus infection - 1-2 courses, cytomegalovirus infection - 2-3 courses, mycoplasmosis, candidiasis, including visceral - 2-3 courses. The break between courses is 5 days. According to clinical indications, therapy can be continued.

Chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of pronounced activity, complicated by liver cirrhosis. The recommended dose for adults is VIFERONЃ 3,000,000 IU, 1 suppository 2 times a day every 12 hours every day for 10 days, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters. Children under the age of 6 months are recommended 300,000-500,000 IU per day; at the age of 6 to 12 months - 500,000 IU per day. Children aged 1 to 7 years are recommended 3,000,000 IU per 1 m2 of body surface area per day. Children over 7 years old are recommended 5,000,000 IU per 1 m2 of body surface area per day.The drug is used 2 times a day after 12 hours for the first 10 days every day, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters. The calculation of the daily dose of the drug for each patient is made by multiplying the recommended dose for a given age by the body surface area calculated from the nomogram to calculate the body surface area by height and weight according to Garford, Terry and Rourke. The calculation of a single dose is carried out by dividing the calculated daily dose by 2 injections, the resulting value is rounded up to the dosage of the suppository.The calculation of the daily dose of the drug for each patient is made by multiplying the recommended dose for a given age by the body surface area calculated from the nomogram to calculate the body surface area in terms of height and weight according to Garford, Terry and Rourke. The calculation of a single dose is carried out by dividing the calculated daily dose by 2 injections, the resulting value is rounded up to the dosage of the suppository.The calculation of the daily dose of the drug for each patient is made by multiplying the recommended dose for a given age by the body surface area calculated from the nomogram to calculate the body surface area in terms of height and weight according to Garford, Terry and Rourke. The calculation of a single dose is carried out by dividing the calculated daily dose by 2 injections, the resulting value is rounded up to the dosage of the suppository.

In chronic viral hepatitis of pronounced activity and cirrhosis of the liver, before plasmapheresis and / or hemosorption, it is recommended to use VIFERONЃ 150,000 IU for children under 7 years old, VIFERONЃ 500,000 IU for children over 7 years old, 1 suppository 2 times a day after 12 h daily for 14 days.

Infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults, including pregnant women as part of complex therapy. The recommended dose for adults is VIFERONЃ 500,000 IU, 1 suppository 2 times a day every 12 hours every day for 5-10 days. According to clinical indications, therapy can be continued. Pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation) are recommended to use the drug VIFERONЃ 500,000 IU, 1 suppository 2 times a day every 12 hours every day for 10 days, then for 9 days 3 times with an interval of 3 days (for fourth day) 1 suppository 2 times a day after 12 hours.Then, every 4 weeks until delivery of VIFERONЃ 150,000 IU, 1 suppository 2 times a day every 12 hours every day for 5 days. If necessary, it is indicated before delivery (from 38 weeks of gestation) the use of VIFERONЃ 500,000 IU, 1 suppository 2 times a day every 12 hours every day for 10 days.

Primary or recurrent herpes infection of the skin and mucous membranes, localized form, mild and moderate course, including urogenital form in adults, including pregnant women. The recommended dose for adults is VIFERONЃ 1,000,000 IU, 1 suppository 2 times a day every 12 hours every day for 10 days or more in case of recurrent infection. According to clinical indications, therapy can be continued. It is recommended to start treatment immediately when the first signs of lesions of the skin and mucous membranes appear (itching, burning, redness).

When treating recurrent herpes, it is advisable to start treatment in the prodromal period or at the very beginning of the manifestation of signs of relapse. Pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation) are recommended to use the drug VIFERONЃ 500,000 IU, 1 suppository 2 times a day every 12 hours every day for 10 days, then for 9 days 3 times with an interval of 3 days (for fourth day) 1 suppository 2 times a day after 12 hours. Then, every 4 weeks until delivery of VIFERONЃ 150,000 IU, 1 suppository 2 times a day every 12 hours every day for 5 days. If necessary, it is indicated before delivery (from 38 weeks of gestation) the use of VIFERONЃ 500,000 IU, 1 suppository 2 times a day every 12 hours every day for 10 days.

Viral meningitis in children aged 4 years and older as part of complex therapy. The recommended dose for children from 4 years to 11 years inclusive - VIFERONЃ 1,000,000 IU 1 suppository 2 times a day every 12 hours every day for 7 days, then 1,000,000 IU 1 suppository 1 time per day (at night) daily for 7 days. For children from 12 years to 18 years old inclusive - VIFERONЃ 3,000,000 IU 1 suppository 2 times a day every 12 hours daily for 7 days, then 3,000,000 IU 1 suppository 1 time a day (at night) daily within 7 days.

Rectal suppositories of white color with a yellowish tinge, bullet-shaped, homogeneous consistency; inhomogeneity of color in the form of marbling and the presence of a funnel-shaped depression on the longitudinal section is allowed; the diameter of the suppository is not more than 10 mm.

1 supp. interferon alpha-2b human recombinant 3,000,000 IU

Excipients: ?-tocopherol acetate - 55 mg, ascorbic acid - 8.1 mg, sodium ascorbate - 16.2 mg, disodium edetate dihydrate - 100 ?g, polysorbate 80 - 100 ?g, cocoa butter base and confectionery fat - up to 1 g.

Suppositories: hypersensitivity to any component of the drug.

Pharmacodynamics

Human recombinant interferon alpha-2b has antiviral, immunomodulatory, antiproliferative properties, inhibits the replication of RNA and DNA viruses. The immunomodulatory properties of interferon alpha-2b, such as an increase in the phagocytic activity of macrophages, an increase in the specific cytotoxicity of lymphocytes to target cells, determine its mediated antibacterial activity. In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alpha-2b increases, its immunomodulatory effect is enhanced, which makes it possible to increase the effectiveness of the body's own immune response to pathogenic microorganisms.

When using the drug, the level of class A secretory immunoglobulins increases, the level of immunoglobulin E is normalized, and the functioning of the endogenous interferon alpha-2b system is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane stabilizing and regenerating properties. It was found that when using the drug VIFERON8, there are no side effects that occur with parenteral administration of interferon alpha-2b drugs, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b. The use of the drug VIFERONЃ as part of a complex therapy allows to reduce the therapeutic doses of antibacterial and hormonal drugs, as well as to reduce the toxic effects of this therapy.Cocoa butter contains phospholipids, which make it possible not to use synthetic toxic emulsifiers in production, and the presence of polyunsaturated fatty acids facilitates the introduction and dissolution of the drug.

Side effects

In rare cases, the development of allergic reactions (skin rashes, itching) is possible. These phenomena are reversible and disappear 72 hours after discontinuation of the drug.

Special conditions

Application during pregnancy and during breastfeeding The drug is approved for use from the 14th week of pregnancy. It has no restrictions for use during breastfeeding.

Impact on the ability to drive vehicles and engage in other activities

Not installed.

Drug interactions

VIFERON, rectal suppositories, compatible and well combined with all drugs used in the treatment of the above diseases (antibiotics, chemotherapy drugs, glucocorticosteroids).